Section Arrow
NUVL.NASDAQ
- Nuvalent
Quotes are at least 15-min delayed:2025/06/26 16:22 EDT
Last
 79.13
+0.04 (+0.05%)
Day High 
79.84 
Prev. Close
79.09 
1-M High
79.97 
Volume 
455.51K 
Bid
70
Ask
90.6
Day Low
77.675 
Open
79.77 
1-M Low
70.25 
Market Cap 
5.68B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 76.79 
20-SMA 76.63 
50-SMA 74.24 
52-W High 113.51 
52-W Low 55.535 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.42/-3.69
Enterprise Value
5.68B
Balance Sheet
Book Value Per Share
14.08
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
VORVor Biopharma0.89+0.3356+60.53%-- 
ADILAdial Pharmaceuticals0.4698+0.2238+90.98%-- 
PSTVPlus Therapeutics0.3666+0.0516+16.38%-- 
ALTAltimmune3.61-4.1-53.18%-- 
ASBPAspire Biopharma Holdings Inc.0.306+0.0664+27.71%-- 
Quotes are at least 15-min delayed:2025/06/26 16:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.